Terms: = Thyroid cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
10 results:
1. circPVT1 regulates medullary thyroid cancer growth and metastasis by targeting miR-455-5p to activate CXCL12/cxcr4 signaling.
Zheng X; Rui S; Wang XF; Zou XH; Gong YP; Li ZH
J Exp Clin Cancer Res; 2021 May; 40(1):157. PubMed ID: 33962657
[TBL] [Abstract] [Full Text] [Related]
2. Clinical association of cxcr4 in primary tumor of papillary thyroid cancer and response to iodine-131 treatment.
Sirakriengkrai K; Tepmongkol S; Keelawat S; Techavijit U
Nucl Med Commun; 2021 Apr; 42(4):396-401. PubMed ID: 33306632
[TBL] [Abstract] [Full Text] [Related]
3. [Expression of chemokine CXCL12 and its receptor (cxcr4 and CXCR7) in different molecular subtypes of human breast carcinoma and the clinical significance].
Wu W; Qian L; Dai J; Ding B; Chen X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Feb; 42(2):147-153. PubMed ID: 28255115
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of CXCL12, cxcr4, and CXCR7 in patients with breast cancer.
Wu W; Qian L; Chen X; Ding B
Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
[TBL] [Abstract] [Full Text] [Related]
5. Well-differentiated thyroid cancer with a minor poorly differentiated component: clonal heterogeneity through the prognostic role of cxcr4 and BRAF analysis.
Rossi ED; Martini M; Capodimonti S; Straccia P; Revelli L; Lombardi CP; Pontecorvi A; Santeusanio G; Larocca LM; Fadda G
Appl Immunohistochem Mol Morphol; 2015 Mar; 23(3):196-201. PubMed ID: 24992171
[TBL] [Abstract] [Full Text] [Related]
6. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract] [Full Text] [Related]
7. Diagnostic value of 16 cellular tumor markers for metastatic thyroid cancer: an immunohistochemical study.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Zhan S; Xie K; Li QQ
Anticancer Res; 2011 Oct; 31(10):3433-40. PubMed ID: 21965758
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical expression of cxcr4 in thyroid carcinomas and thyroid benign lesions.
He X; Wei Q; Zhang X; Xiao J; Jin X; Zhu Y; Cui B; Ning G
Pathol Res Pract; 2010 Oct; 206(10):712-5. PubMed ID: 20646838
[TBL] [Abstract] [Full Text] [Related]
9. Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis.
Liang H; Zhong Y; Luo Z; Huang Y; Lin H; Luo M; Zhan S; Xie K; Ma Y; Li QQ
Int J Biol Markers; 2010; 25(1):38-45. PubMed ID: 20306451
[TBL] [Abstract] [Full Text] [Related]
10. Biological role and potential therapeutic targeting of the chemokine receptor cxcr4 in undifferentiated thyroid cancer.
De Falco V; Guarino V; Avilla E; Castellone MD; Salerno P; Salvatore G; Faviana P; Basolo F; Santoro M; Melillo RM
Cancer Res; 2007 Dec; 67(24):11821-9. PubMed ID: 18089812
[TBL] [Abstract] [Full Text] [Related]
